Voltarelli Júilio C, Couri Carlos E B, Rodrigues Maria C, Moraes Daniela A, Stracieri Ana-Beatriz P L, Pieroni Fabiano, Navarro George, Leal Angela M O, Simões Belinda P
Department of Clinical Medicine, RibeirBo Preto School of Medicine, University of São Paulo, Brazil.
Indian J Exp Biol. 2011 Jun;49(6):395-400.
The present review discusses the use of autologous hematopoietic stem cell transplantation (HSCT) for the treatment of diabetes mellitus type 1 (DM 1). It has been observed that high dose immunosuppression followed by HSCT shows better results among other immunotherapeutic treatments for the disease as the patients with adequate beta cell reserve achieve insulin independence. However, this response is not maintained and reoccurrence of the disease is major a major challenge to use HSCT in future to prevent or control relapse of DM 1.
本综述讨论了自体造血干细胞移植（HSCT）在1型糖尿病（DM 1）治疗中的应用。据观察，在该疾病的其他免疫治疗方法中，高剂量免疫抑制后进行HSCT显示出更好的效果，因为具有足够β细胞储备的患者可实现胰岛素自主。然而，这种反应不能持续，疾病复发是未来使用HSCT预防或控制DM 1复发的一大主要挑战。
